Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session Item

Head and neck
Poster (digital)
Clinical
TOXICITY PROFILE OF 100 OROPHARYNGEAL CANCER PATIENTS TREATED WITH MODERN APPROACHES
Daniela Alterio, Italy
PO-1088

Abstract

TOXICITY PROFILE OF 100 OROPHARYNGEAL CANCER PATIENTS TREATED WITH MODERN APPROACHES
Authors:

Daniela Alrerio1, Giulia Corrao2, Stefano Zorzi3, Giovanni Agostini4, Giulia Marvaso2, Stefania Volpe2, Luca Bergamaschi2, Cristiana Pedone2, Jessica Franzetti2, Cecilia Bonfiglio2, Anna Maria Camarda2, Marta Tagliabue5, Maria Cossu Rocca6, Mohssen Ansarin3, Barbara Alicja Jereczek-Fossa2

1IEO, European Institute of Oncology IRCCS, Division of Radiation Oncology, Milan, Italy; 2IEO, European Institute of Oncology IRCCS; University of Milan, Division of Radiation Oncology; Department of Oncology and Hematoncology, Milan, Italy; 3IEO, European Institute of Oncology IRCCS, Division of Otolaryngology and Head and Neck Surgery, Milan, Italy; 4University of Perugia, Section of Otolaryngology-Head and Neck Surgery, Milan, Italy; 5IEO, European Institute of Oncology IRCCS; University of Sassari, Division of Otolaryngology and Head and Neck Surgery; Department of Biomedical Sciences, Milan, Italy; 6IEO, European Institute of Oncology IRCCS, Department of Medical Oncology, Urogenital and Head and Neck Tumors Medical Treatment, Milan, Italy

Show Affiliations
Purpose or Objective

Locally advanced oropharyngeal cancers (LAOPCs) can be treated with both non-surgical (chemoradiation) and surgical approaches. Whether the use of modern techniques (Intensity Modulated Radiotherapy -IMRT- and Transoral Robotic Surgery - TORS) could impact the toxicity profile of these two strategies has not been well established yet. Aim of the present study was to compare acute and long-term treatment-related side effects of two cohorts of patients (pts) with LAOPC treated with curative IMRT or TORS followed by postoperative IMRT.

Material and Methods
We retrospectively reviewed pts treated at our Institute from 2015 to 2020 for LAOPC. Inclusion criteria were: 1) locally advanced stages (III and IV according to AJCC 7th Ed) 2) treated with IMRT (+/- chemotherapy - CT) or TORS followed by postoperative radiotherapy (PORT). Exclusion criteria were: 1) recurrent tumors 2) previous treatments on the head and neck region 4) 3D conformal radiotherapy technique 3) palliative treatments. Acute (at the end of the IMRT course) and early-late (at one year from the end of IMRT course) toxicities were reported according to Common Terminology Criteria Adverse Events (CTCAE v.3.04). Enteral nutrition, tracheostomia and oesophageal stricture occurred at any time during the follow-up period were also reported.

Results

A total of 100 pts matched inclusion criteria. Median age was 61 years (range 43-84) and 75% were male. Seventy-two (72%) pts underwent IMRT (90% concurrent CT) while 28 (28%) pts have been treated with TORS followed by PORT IMRT (61% concurrent CT). Tumor and patient characteristics have been reported in Table 1. After a median follow up of 24 months (range 1.4-74.4 months), all pts were alive and 86% and 87% resulted without disease in IMRT and TORS group, respectively. Locoregional recurrences occurred in 11% and 12% of pts treated with IMRT and TORS, respectively. Acute and early-late toxicity profile have been reported in Table 2. Eight (12%) and 4 (4%) pts required enteral nutrition during the radiation course in the IMRT and TORS group, respectively. Twenty one (30%) and two (7%) pts lost more than 10% (G3 toxicity) of their baseline value in the IMRT and TORS cohort, respectively. Tracheostomy, enteral nutrition and oesophageal stricture occurred at any time during the follow up period in 6%, 3%, 0% and 1%, 3%, 0% pts treated with IMRT and TORS, respectively.


Conclusion

Pts with LAOPCs treated with modern techniques experienced a favorable toxicity profile regardless the treatment approach. A higher proportion of G3 weight loss was found in the curative IMRT cohort compared to the TORS cohort. This finding could probably due to the presence of macroscopic disease which could cause mechanic dysphagia, the higher rate of advanced primary tumor stage and concurrent chemotherapy in this group of pts compared to those treated with TORS.